Sporamin suppresses growth of human esophageal squamous cell carcinoma cells by inhibition of NF-κB via an AKT-independent pathway

CUI-JUAN QIAN, YONG-XIAO QI, XIAO-YING CHEN, JU-PING ZENG and JUN YAO

Institute of Tumor, School of Medicine, Taizhou University, Taizhou, Zhejiang 318000, P.R. China

Received September 11, 2016; Accepted June 15, 2017

DOI: 10.3892/mmr.2017.7772

Abstract. The aim of the present study was to determine whether sporamin, a trypsin inhibitor, suppresses the growth of human esophageal squamous cell carcinoma (ESCC) cells in vitro. Sporamin treatment led to the suppression of viability and proliferation of human ESCC cell lines, EC9706 and EC109, as determined by MTT and [3H] thymidine incorporation assays, respectively. Flow cytometry and fluorescence microscopy demonstrated that sporamin significantly induced apoptosis in EC9706 and EC109 cells. Western blotting demonstrated that sporamin downregulated the expression of Bcl-2 and Bcl-2 like 1, and upregulated the expression of Bcl-2-associated X in EC9706 and EC109 cells. In addition, marked inhibition of nuclear factor (NF)-κB activation was observed in sporamin-treated EC9706 and EC109 cells by an electrophoretic mobility shift assay. Sporamin treatment also resulted in reduced expression levels of phosphorylated (p)-NF-κB inhibitor α and nuclear NF-κB p65. However, the expression levels of p-protein inase (AKT) and its downstream target, p-p70 S6 kinase, were not markedly altered following sporamin treatment. In conclusion, sporamin may suppress the growth of human ESCC cells via NF-κB-dependent and AKT-independent mechanisms and may act as a promising natural therapeutic agent for the treatment of human ESCC.

Introduction

Esophageal cancer (EC) is the sixth most common cause of cancer-associated deaths worldwide (1) and esophageal squamous cell carcinoma (ESCC) accounts for 70% of EC cases (2). Once diagnosed, the prognosis is poor in the majority of patients with advanced EC, regardless of the stage (3). Despite advances in the traditional treatments for EC, the mortality from EC has not improved greatly (4). Therefore, it is necessary to develop novel therapeutic methods that may improve the survival rate of patients with advanced EC.

Sporamin, a trypsin inhibitor, is the primary soluble storage protein in sweet potato tuberous roots, and has been identified as an antitumor agent that induces antitumor effects in certain types of tumor cells (5,6). However, to the best of our knowledge, the mechanisms underlying its diverse biological effects have not previously been investigated in ESCC cells. Therefore, the effects of sporamin on cell viability, cell proliferation activity and apoptosis were investigated in EC9706 and EC109 human ESCC cell lines.

Nuclear factor (NF)-κB has been associated with the promotion of esophageal tumorigenesis by protecting tumor cells from cell death (7). AKT is a protein kinase that transduces signals from oncoproteins or growth factors, such as epidermal growth factor receptor (EGFR), to downstream targets in tumor cells (8). NF-κB signaling may be activated via the AKT signaling pathway (9). Therefore, in the present study, the effects and underlying mechanisms of sporamin treatment on NF-κB and AKT signaling pathways in human ESCC cells were investigated.

The authors’ previous studies have demonstrated that sporamin treatment suppresses the growth of human tongue carcinoma cells in vitro (6). However, the detailed effects and mechanisms of sporamin on ESCC cells have not been well characterized. To improve the understanding of the effects and underlying mechanisms of sporamin on ESCC cells, an MTT assay, [3H] thymidine incorporation assay, morphological and flow cytometry analysis, western blotting and electrophoretic mobility shift assay (EMSA) were performed in the present study.

Materials and methods

Cell line and materials. EC109 and EC9706 cells (Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China), which are well and poorly differentiated human ESCC cell lines, respectively, were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA)
supplemented with 10% fetal bovine serum (FBS), 10 U/ml penicillin and 10 µg/ml streptomycin at 37°C and 5% CO2. Sporamin, a primary soluble protein in sweet potatoes with trypsin inhibitory activity, was purified from fresh sweet potato tuberous roots (Ipomoea batatas cv. Tainong 57; Hangzhou Lianhua Huashang Group Co., Zhejiang, China), as described previously (6). The primary antibodies against Bcl-2 (catalog no. sc-509), Bcl-2 like 1 (Bcl-XL; catalog no. sc-7122), Bcl-2-associated X (Bax; catalog no. sc-23959) and NF-κB p65 (catalog no. sc-8008) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). AKT (catalog no. 9272), phosphorylated (p)-AKT (Thr308; catalog no. 4056), p70 S6 kinase (catalog no. 9202), p-p70 S6 kinase (Thr421/Ser424; catalog no. 9204), NF-κB inhibitor α (IκBα; catalog no. 9242) and p-IκBα (Ser32; catalog no. 2859) primary antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA), and tubulin (catalog no. ab59680), histone (H2A (catalog no. ab13923) and β-actin (catalog no. ab8227) primary antibodies were purchased from Abcam (Cambridge, UK).

MTT assay. The in vitro cell viability of EC109 and EC9706 cells treated with sporamin was measured using the MTT assay. A total of 1x10^5 cells/well were cultured in 96-well plates and incubated with 0, 12.5, 25, 50 or 100 µM sporamin for 24, 48, 72 h at 37°C. Dimethyl sulfoxide (DMSO) was used as a control instead of sporamin. Medium was discarded and wells were replaced with 100 µl fresh medium containing 10% MTT solution (5 mg/ml stock) at 37°C for 4 h, 100 µl DMSO was subsequently added to each well before agitating the plates at room temperature for 10 min. Colorimetric determination of MTT reduction was determined at a wavelength of 570 nm using a microplate ELISA reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

[^H] thymidine incorporation assay. The in vitro cell proliferation activity of EC109 and EC9706 cells treated with sporamin was measured by a[^H] thymidine incorporation assay (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). A total of 2.5x10^5 cells/well were cultured in 24-well plates in DMEM with 10% dialyzed and charcoal-stripped FBS.
When cells reached 80% confluence, the cultures were rinsed in phenol-free DMEM medium and incubated with 0, 12.5, 25, 50 or 100 µM sporamin in phenol-free and serum-free DMEM for 24, 48 and 72 h. [3H] thymidine (1.35x10^4 Bq/l) was added and cultured with cells for a further 12 h at 37˚C. Subsequently, the supernatant was aspirated and excess [3H] thymidine was removed by washing with PBS. Finally, 0.2 mol/l NaOH was added at 37°C and radioactivity ([3H] thymidine incorporation activity) was determined by scintillation counting (LS6500; Beckman Instruments, Inc., Fullerton, CA, USA).

**Morphological determination and quantification of apoptosis.** Cells were cultured in 12-well plates at a density of 2x10^4 cells per well and incubated with 25 µM sporamin or DMSO for 48 h. Bcl-XL, Bcl-2 like 1; Bax, Bcl-2-associated X.
48 h at 37˚C. Cells were then fixed with 4% cold paraformaldehyde at 4˚C for 15 min (pH 7.4) and stained with 0.5 µg/ml DAPI (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) for 5 min at room temperature. The cells were subsequently visualized under a fluorescence microscope (model DM14000B; Olympus Corporation, Tokyo, Japan) using a 360-370 nm excitation light and a 420-460 nm emission filter. Cells undergoing apoptosis exhibit profound structural alterations, including apoptotic chromatin condensation, nuclear envelope shrinkage and fragmentation. Apoptotic morphological changes in the nucleus were distinguished from intact nuclei and counted, and the percentages were subsequently calculated. A total of six randomly chosen fields of view were examined with a minimum number of 500 cells scored in each condition.

Flow cytometry analysis for apoptosis. Apoptosis was measured using an Annexin V-Fluorescein Isothiocyanate (FITC)/Propidium Iodide (PI) Apoptosis Detection kit (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Briefly, 1.5x10⁶ cells/well were incubated with 25 µM sporamin or DMSO for 48 h at 37˚C. Both attached and floating cells were pooled, pelleted by centrifugation at 1000 g for 5 min, 4˚C, washed twice with cold PBS and 1x10⁶ cells/ml were resuspended in 1X binding buffer [10 mM hydroxyethyl piperazine ethanesulfonic acid, (pH 7.4), 2.5 mM CaCl₂, and 140 mM NaOH]. A total of 1x10⁵ cells were transferred to a 5-ml tube and stained with 5 µl annexin V-FITC and 5 µl PI for 15 min at room temperature in the dark. Finally, 400 µl 1X binding buffer was added to each tube and apoptosis was determined using a BD FACSCanto II flow cytometer with BD Accuri™ C6 software (BD Biosciences, San Jose, CA, USA).

Western blotting. Total protein was extracted from treated cells using M-Per Mammalian Protein Extraction reagent (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Nuclear fractions were prepared using a Nuclear Protein Extraction kit (Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's protocol. The protein concentrations were determined using a Bradford assay. Cell protein extracts were either used immediately or stored at -70˚C.

For SDS-PAGE, a total of 20 µg protein was loaded into each well of 10-12% gel and electrophoresed at 98 V. Proteins on the gel were transferred onto a polyvinylidene fluoride membrane by wet electrotransfer for 2 h. The membrane was blocked in 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA) in TBS containing 0.1% Tween-20 at room temperature for 90 min. The primary antibodies (all used at a 1:200 dilution) against Bcl-2, Bcl-XL, Bax, NF-κB p65, IxBα, AKT, p70 S6 kinase, p-IκBα (Ser32), p-AKT (Thr308), p-p70 S6 kinase (Thr421/Ser424), tubulin, H2A and β-actin were added separately and incubated with the membrane overnight at 4˚C. The membranes were subsequently washed three times with TBS/0.1% Tween-20. The following day, membranes were incubated with horseradish peroxidase-conjugated anti-rabbit (1:2,000; cat. no. 7074; Cell Signaling Technology, Inc.), anti-mouse (1:2,000; cat. no. 7076; Cell Signaling Technology, Inc.), and anti-goat (1:2,000; cat. no. sc-2350; Santa Cruz Biotechnology) immunoglobulin G secondary antibodies. The membranes were subsequently washed four times with TBS/0.1% Tween-20, 5 min per wash. All bands were visualized using Pierce™ enhanced chemiluminescence Western Blotting Substrate (Merck KGaA, Darmstadt, Germany) and scanned using an LAS-4000 imaging system (Fujifilm, Tokyo, Japan).

EMSA. For EMSA, cells were treated with 0, 12.5, 25 or 50 µM sporamin for 48 h at 37˚C. EMSA was performed using a commercial kit (Gel Shift Assay System; Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. Nuclear Protein Extraction kit (Beyotime Institute of Biotechnology, Haimen, China) was adopted to prepare nuclear fractions, according to the manufacturer's protocol. A bicinchoninic assay was used to determine the protein concentration. Nuclear protein (2 µg) was preincubated in binding buffer [10 mM Tris-Cl, (pH 7.5), 50 mM NaCl, 1 mM MgCl₂, 0.5 mM EDTA, 4% glycerol, 0.5 mM DTT and 0.05 g/l poly (deoxyinosinic deoxyctydilic acid)] for 15 min at room temperature. After addition of 1 µl ³²P-labeled oligonucleotide probe (1.75 pmol/µl), the incubation was continued for 30 min at room temperature. The reaction was stopped by adding 1 µl gel loading buffer and the mixture was subjected to 4% non-denaturing polyacrylamide gel electrophoresis in 0.5X Tris/Borate/EDTA buffer. The gel was vacuum-dried and exposed to X-ray film at -70˚C. The dried gels were visualized by autoradiography using x-ray film.

Statistical analysis. Data are presented as the mean ± standard deviation. A one-way analysis of variance followed by Tukey's post hoc test, or student's t-test were used to compare differences between groups using SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

**Sporamin inhibits cell viability and proliferation activity in ESCC cells.** To investigate the effects of sporamin on cell viability and the proliferation of ESCC cells, EC9706 and EC109 cells were treated with sporamin at increasing concentrations (12.5, 25, 50 and 100 µM) and for varying durations (24, 48 and 72 h), and cell viability and proliferation were determined using an MTT assay (Fig. 1A) and a [³H]thymidine incorporation assay (Fig. 1B), respectively. The results demonstrated that sporamin significantly inhibited cell viability and proliferation activity in a concentration- and time-dependent manner.

**Sporamin induces cell apoptosis in ESCC cells.** When EC9706 and EC109 cells were treated with 25 µM sporamin for 48 h, the inhibition of cell viability and proliferation activity were significant. Therefore, cells were treated with 25 µM sporamin for 48 h for further experiments. Apoptotic cells were examined under fluorescence microscopy following DAPI staining. Following exposure to sporamin, the cell volume reduced, the chromatin became condensed and the nuclei became fragmented, compared with DMSO-treated cells (Fig. 2A). Compared with DMSO-treated control cells, the percentage of apoptotic cells was increased significantly following sporamin treatment in EC9706 and EC109 cells (Fig. 2B).

As sporamin induced morphological changes associated with apoptosis at a concentration of 25 µM for 48 h, annexin V and PI staining was additionally performed to determine cell apoptosis. The results demonstrated that the percentages of apoptotic cells (annexin V positive cells) were increased significantly following culture with sporamin, compared with the DMSO control cells (Fig. 2C and D). These results
indicate that sporamin may induce cell apoptosis in EC9706 and EC109 cells.

Sporamin induces the downregulation of Bcl-2 and Bcl-XL, and upregulation of Bax in ESCC cells. As Bcl-2, Bcl-XL and Bax are involved in the promotion of apoptosis, the expression levels of Bcl-2, Bcl-XL and Bax in EC9706 and EC109 cells were measured by western blotting, to identify the potential underlying molecular basis for the effects of sporamin on ESCC cells. The results indicated that sporamin inhibited the expression of the anti-apoptotic proteins, Bcl-2 and Bcl-XL, and induced the expression of the proapoptotic protein Bax, in a concentration-dependent manner in EC9706 and EC109 cells (Fig. 3). The results indicate that sporamin may induce apoptosis via the regulation of Bcl-2, Bcl-XL and Bax expression.

Sporamin inhibits NF-κB DNA-binding activity in ESCC cells. As Bcl-2 and Bcl-XL may be regulated by NF-κB (10), it was hypothesized that sporamin may mediate its effects by regulating NF-κB. Therefore, nuclear extracts of EC9706 and EC109 cells treated with various concentrations of sporamin (12.5, 25 and 50 μM) or control diluent were prepared and NF-κB DNA-binding activity was examined by EMSA. As demonstrated in Fig. 4, a marked reduction of NF-κB DNA-binding activity was observed in sporamin-treated cells in a concentration-dependent manner. These results indicate that sporamin may inhibit NF-κB DNA-binding activity.

Sporamin inhibits NF-κB activation via an AKT-independent mechanism in ESCC cells. Treatment with sporamin resulted in reduced nuclear expression of NF-κB p65 in a concentration-dependent manner in EC9706 and EC109 cells (Fig. 5A and B). Consistently, there was a marked reduction in the expression levels of p-IκBα (Fig. 5C). However, the expression and phosphorylation levels of AKT, or its downstream target, p-p70 S6 kinase, were not altered following sporamin treatment (Fig. 5C). These results indicate that NF-κB inhibition by sporamin may be partially regulated via the dephosphorylation of IκBα, without inhibition of AKT.

Discussion

In the present study, human ESCC cell lines (EC9706 and EC109) were treated with sporamin. The results demonstrated that sporamin suppressed the cell growth of ESCC cells in vitro, which may be mediated via NF-κB inhibition. In addition, NF-κB DNA-binding activity, phosphorylation of IκBα and nuclear expression of NF-κB were reduced in sporamin-treated ESCC cells.

To the best of our knowledge, the present study is the first to demonstrate that sporamin exhibits inhibitory effects on cell viability and proliferation in ESCC cells, and the inhibitory effects were positively associated with treatment duration and concentration. Apoptosis is a process that eliminates unwanted cells in various physiological processes. Dysregulation of apoptosis is implicated in carcinogenesis, and inhibition of cell viability and proliferation activity may indicate the induction of apoptosis (11). Therefore, the present study investigated whether apoptosis contributes to the inhibition of cell viability and proliferation following sporamin treatment in EC9706 and EC109 cells. Following sporamin treatment, EC9706 and EC109 cells exhibited features of apoptosis. Typical morphological features of apoptosis and percentages of apoptotic cells were demonstrated by DAPI nuclear staining and flow cytometric analysis, respectively. In addition, the results revealed that sporamin induced the downregulation of Bcl-2 and Bcl-XL protein expression, and upregulation of Bax protein levels. This indicates that sporamin may induce apoptosis via the regulation of Bcl-2, Bcl-XL and Bax and NF-κB protein expression.

As it is established that NF-κB enhances tumor cell growth via the regulation of Bcl-2 and Bcl-XL (10), the present study investigated whether sporamin may inhibit NF-κB DNA-binding activity using EMSA, and the results indicated that sporamin may suppress the cell growth of human ESCC cells, at least partially, via the inhibition of NF-κB activation. NF-κB is a heterodimer consisting of p50 and p65 subunits, and, when inactive, is sequestered in the cytoplasm as it is bound to its endogenous inhibitor, IκB, which consists of α and β subunits (12,13). IκBα is phosphorylated by the IκB kinase complex, and this phosphorylation leads to the ubiquitination and subsequent degradation of p-IκBα, which allows NF-κB to migrate from the cytoplasm to the nucleus, where it subsequently induces target gene expression (12,13). In the present study, sporamin inhibited NF-κB activation, which may, at least partially, occur via reduced phosphorylation of IκBα.

NF-κB is additionally activated via various other signaling pathways (14). Of these, AKT signaling induces NF-κB activation in human hepatocellular carcinoma cells (15). Overexpression of EGFR and inactivation of the tumor suppressor gene phosphatase and tensin homolog may result in activation and/or expression of AKT and its downstream targets, including p70 pS6 kinase (16-18). However, in the present study, sporamin did not affect the expression and phosphorylation levels of AKT, or its downstream target p-p70 S6 kinase, indicating that sporamin may suppress cell growth of ESCC cells via an AKT-independent mechanism.

In conclusion, sporamin may inhibit cell viability and proliferation, and induce apoptosis in ESCC cells. In addition, inhibition of NF-κB activation was accompanied by reduced Bcl-2 and Bcl-XL expression, and increased Bax expression levels in sporamin-treated ESCC cells. A better understanding of the underlying mechanisms and further identification of additional downstream effectors of sporamin will help guide the development of more effective agents to treat human ESCC.

Acknowledgements

The present study was supported by grants from the Natural Science Foundation of Zhejiang Province (grant no. LY16H160033), the Public Welfare Technical Applied Research Project of Zhejiang Province (grant no. 2016C33189), the Science and Technology Plans of Taizhou City (grant no. 1701yw07), and the National College Students' Innovation and Entrepreneurship Training Program (grant no. 201710350008).
References